The global over-the-counter (OTC) pain medication market is poised for steady growth, with its market size expected to attain ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for ...

Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...

Key drugs in shortage include ADHD medications, pain treatments ... Fresenius Kabi, Hikma, Pfizer, and Piramal Critical Care. Conversely, Fresenius Kabi, Hikma, and Pfizer continue to face ...

Pfizer acquired Global Blood Therapeutics ... in addition to other debilitating symptoms caused by the medication including pain and swelling. While on the drug, the plaintiff suffered a stroke ...

Pfizer has won European Commission approval of ... or syringe for those with severe hemophilia A or B. The U.S. Food and Drug Administration approved Hympavzi in October.